
CytomX Therapeutics Inc
NASDAQ:CTMX

Intrinsic Value
The intrinsic value of one
CTMX
stock under the Base Case scenario is
0.285
USD.
Compared to the current market price of 2.275 USD,
CytomX Therapeutics Inc
is
Overvalued by 87%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
CytomX Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
CytomX Therapeutics Inc
Balance Sheet Decomposition
CytomX Therapeutics Inc
Current Assets | 86.6m |
Cash & Short-Term Investments | 79.9m |
Receivables | 2m |
Other Current Assets | 4.8m |
Non-Current Assets | 11.9m |
PP&E | 9.3m |
Intangibles | 1.5m |
Other Non-Current Assets | 1.1m |
Free Cash Flow Analysis
CytomX Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
CytomX Therapeutics Inc
Revenue
|
147.6m
USD
|
Operating Expenses
|
-111.6m
USD
|
Operating Income
|
36m
USD
|
Other Expenses
|
5.6m
USD
|
Net Income
|
41.6m
USD
|
CTMX Profitability Score
Profitability Due Diligence
CytomX Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Score
CytomX Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
CTMX Solvency Score
Solvency Due Diligence
CytomX Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Score
CytomX Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTMX Price Targets Summary
CytomX Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CTMX
is 5.61 USD
with a low forecast of 3.535 USD and a high forecast of 8.4 USD.
Dividends
Current shareholder yield for CTMX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CTMX
stock under the Base Case scenario is
0.285
USD.
Compared to the current market price of 2.275 USD,
CytomX Therapeutics Inc
is
Overvalued by 87%.